GlassScriptPhysician profile
Paul D Forman
NPI 1871606004
$1,840.77
in general payments reported to CMS, 2019-2025
22 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.97 · 2020: $47.89 · 2021: $481 · 2022: $427 · 2023: $246 · 2024: $258 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $272.41 | 2021-2025 | Nucala |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.89 | 2024-2025 | Caplyta |
| Pfizer INC. | $156.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $99.53 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $90.30 | 2019-2022 | |
| Novo Nordisk INC | $78.62 | 2021-2022 | |
| Eisai INC. | $55.84 | 2021 | |
| Exact Sciences Corporation | $50.46 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $50.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.25 | 2022-2024 | |
| Amgen INC. | $38.33 | 2019-2022 | |
| Indivior INC. | $35.51 | 2024-2025 | Sublocade |
| Amarin Pharma, INC. | $34.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.22 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $19.00 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Acadia Pharmaceuticals INC | $18.50 | 2024 | Daybue |
| Alkermes, INC. | $17.41 | 2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $17.15 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.58 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $14.46 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.